Ascendis Pharma A/S (ASND) News Today $133.75 -0.63 (-0.47%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 9:54 PM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Holdings Increased by Capital International InvestorsCapital International Investors grew its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,191,312 shares of the biotechnology compJuly 26 at 2:52 AM | americanbankingnews.comCantor Fitzgerald Brokers Raise Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)July 25 at 8:47 AM | marketbeat.comAscendis Pharma A/S Expected to Earn FY2024 Earnings of ($4.00) Per Share (NASDAQ:ASND)Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a note issued to investors on Tuesday, July 23rd. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology compJuly 24 at 2:46 PM | finance.yahoo.comDespite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 yearJuly 23, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Seven Eight Capital LPSeven Eight Capital LP decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 75.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,597 shares of the biotechnology company's stockJuly 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Bought by Acadian Asset Management LLCAcadian Asset Management LLC grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1,461.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,492 shares of the biotechnology company's stockJuly 21, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Receives $179.00 Consensus Target Price from BrokeragesJuly 18, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Moderate Buy" by AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have assiJuly 16, 2024 | marketbeat.comSei Investments Co. Sells 15,644 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Sei Investments Co. trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 346,186 shares of the biotechnology company's stock after selling 15,644 shares during the period. Sei InvestmenJuly 13, 2024 | marketbeat.comTimesSquare Capital Management LLC Reduces Stake in Ascendis Pharma A/S (NASDAQ:ASND)TimesSquare Capital Management LLC lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 27.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,698 shares of the bioteJuly 11, 2024 | marketbeat.com6,564 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by GSA Capital Partners LLPGSA Capital Partners LLP bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,564 shares of the biotechnology company's stJuly 10, 2024 | marketbeat.comBNP Paribas Financial Markets Has $11.42 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)BNP Paribas Financial Markets lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4,231.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 75,540 shares of the biotechnology company's stock after purchasing an additional 73,7July 6, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC cut its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 189,208 shares of the biotechnology company's stoJune 25, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by TD CowenTD Cowen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating and boosted their price target for the stock from $156.00 to $175.00 in a report on Tuesday.June 24, 2024 | globenewswire.comData from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024June 19, 2024 | marketbeat.comGoldman Sachs Group Inc. Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 422,854 shares of the biotechnology company's stock after purchasing an additional 12,881 sharesJune 17, 2024 | marketbeat.comWellington Management Group LLP Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND)Wellington Management Group LLP lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 85.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,248,293 shares of the biotechnology company's stock after selling 18,663,June 16, 2024 | marketbeat.comPerceptive Advisors LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 132,176 shares of theJune 12, 2024 | marketbeat.comADAR1 Capital Management LLC Purchases Shares of 45,884 Ascendis Pharma A/S (NASDAQ:ASND)ADAR1 Capital Management LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 45,884 shares of the biotechnology company's stock, valuedJune 12, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.4%Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.4%June 11, 2024 | marketbeat.comSei Investments Co. Has $45.57 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Sei Investments Co. lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 361,830 shares of the biotechnology company's stock after selling 34June 10, 2024 | marketbeat.comAvoro Capital Advisors LLC Increases Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,755,555 shares of the biotechnology company's stock after buying an additional 85,55June 9, 2024 | marketbeat.comVestal Point Capital LP Acquires Shares of 625,000 Ascendis Pharma A/S (NASDAQ:ASND)Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 625,000 shares of the biotechnology company's stock, valued at approximately $78,719,00June 8, 2024 | marketbeat.comSeven Eight Capital LP Acquires Shares of 18,636 Ascendis Pharma A/S (NASDAQ:ASND)Seven Eight Capital LP purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,636 shares of the biotechnology company's stock,June 6, 2024 | marketbeat.com51,700 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Gray FoundationGray Foundation purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,700 shares of the biotechnologJune 5, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Affinity Asset Advisors LLCAffinity Asset Advisors LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 56.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the biotechnology companyJune 4, 2024 | globenewswire.comAscendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | globenewswire.comAscendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024June 2, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest UpdateAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 3,460,000 shares, a decrease of 6.5% from the April 30th total of 3,700,000 shares. Based on an average daily trading volume, of 370,500 shares, the short-interest ratio is currently 9.3 days.June 2, 2024 | marketbeat.comHsbc Holdings PLC Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND)Hsbc Holdings PLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,107 shares of the biotechnoloJune 1, 2024 | marketbeat.comEvoke Wealth LLC Acquires New Shares in Ascendis Pharma A/S (NASDAQ:ASND)Evoke Wealth LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,069 shares of the biotechnology company's stock, vaMay 30, 2024 | globenewswire.comAscendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024May 29, 2024 | marketbeat.comTrexquant Investment LP Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Trexquant Investment LP bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 9,868 shares of the biotechnology company's stock, valued at approximately $1,243,000. Other hedge fundsMay 29, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of "Moderate Buy" from AnalystsAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy ratingMay 27, 2024 | marketbeat.comArtisan Partners Limited Partnership Sells 246,181 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Artisan Partners Limited Partnership cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,749,227 shares of the biotechnologyMay 25, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Position Increased by Westfield Capital Management Co. LPWestfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,030,634 shMay 23, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Raised to "Hold" at StockNews.comStockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday.May 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7%Ascendis Pharma A/S (NASDAQ:ASND) Trading 7% HigherMay 18, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) is Matisse Capital's 5th Largest PositionMatisse Capital grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,635 shares of the biotechnology comMay 17, 2024 | nasdaq.comAugust 16th Options Now Available For Ascendis Pharma (ASND)May 16, 2024 | markets.businessinsider.comAnalyst Issues ‘Buy’ Rating on Ascendis Pharma, Anticipates FDA Approval for TransCon PTHMay 15, 2024 | markets.businessinsider.comPositive Outlook on Ascendis Pharma with Buy Rating Amid Expected US Approval of TransCon PTHMay 15, 2024 | finance.yahoo.comFDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three MonthsMay 15, 2024 | marketbeat.com151,587 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by First Turn Management LLCFirst Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology companMay 15, 2024 | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday.May 15, 2024 | stockhouse.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with HypoparathyroidismMay 14, 2024 | finance.yahoo.comUPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | finance.yahoo.comUS Equity Markets Close Higher Tuesday as Producer Prices RiseMay 14, 2024 | reuters.comFDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | globenewswire.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address We just added a $300 account credit to your MarketBeat subscription (Ad)MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days. Start Your Risk-Free Trial Here ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼1.010.62▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼114▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today TEVA News Today GMAB News Today RPRX News Today BMRN News Today BGNE News Today UTHR News Today SRPT News Today VTRS News Today RDY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.